Bioton (LTS:0DTR) Land And Improvements : zł0.0 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Bioton Land And Improvements?

Bioton's land and improvements for the quarter that ended in Mar. 2024 was zł0.0 Mil.

Bioton Land And Improvements Historical Data

The historical data trend for Bioton's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioton Land And Improvements Chart

Bioton Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Land And Improvements

Get a 7-Day Free Trial

Bioton Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Land And Improvements	Get a 7-Day Free Trial															-	-	-	-	-

Bioton Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Bioton (LTS:0DTR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioton SA (LTS:0DTR) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

BIO:Poland 7U5:Germany

Address

Ul. Staro?ci?ska 5, Warszawa, POL, 02-516

Website

http://www.bioton.pl

Bioton SA is a Poland based company engaged in the principal business activity of manufacturing medicines and pharmaceutical preparations and production of pharmaceutical substances. The products of the company include recombinant human insulin in pharmaceutical substance form and as preparations for injections; glimepiride, an oral hypoglycemic drug; and metformin, an oral hypoglycemic drug. Its products line focuses on diet supplements, products for particular nutritional uses and cosmetics dedicated to patients with certain health problems. The group operates in Poland and internationally, of which majority of the revenue is derived from Poland.

Bioton (LTS:0DTR) Headlines

No Headlines